e10vq
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2008
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number 001-33155
IPG PHOTONICS CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
04-3444218
(I.R.S. Employer
Identification Number) |
|
|
|
50 Old Webster Road, Oxford, Massachusetts
(Address of principal executive offices)
|
|
01540
(Zip code) |
(508) 373-1100
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. YES þ NO o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in
Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated
filer þ
|
|
Non-accelerated filer o
|
|
Smaller reporting
company o |
|
|
|
(Do not check if a smaller reporting company) |
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act). YES o NO þ
As
of May 6, 2008, there were 44,277,252 shares of the registrants common stock issued and
outstanding.
PART IFINANCIAL INFORMATION
ITEM 1. UNAUDITED INTERIM FINANCIAL STATEMENTS
IPG PHOTONICS CORPORATION
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2008 |
|
|
2007 |
|
|
|
(In thousands, except share and per |
|
|
|
share date) |
|
ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
38,698 |
|
|
$ |
37,972 |
|
Marketable securities, at fair value |
|
|
1,000 |
|
|
|
6,950 |
|
Accounts receivable, net |
|
|
37,269 |
|
|
|
33,946 |
|
Inventories, net |
|
|
69,630 |
|
|
|
60,412 |
|
Income taxes receivable |
|
|
2,252 |
|
|
|
3,145 |
|
Prepaid expenses and other current assets |
|
|
9,308 |
|
|
|
7,071 |
|
Deferred income taxes |
|
|
7,215 |
|
|
|
6,195 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
165,372 |
|
|
|
155,691 |
|
DEFERRED INCOME TAXES |
|
|
2,555 |
|
|
|
2,795 |
|
PROPERTY, PLANT AND EQUIPMENT, Net |
|
|
107,010 |
|
|
|
96,369 |
|
OTHER ASSETS |
|
|
12,818 |
|
|
|
8,466 |
|
|
|
|
|
|
|
|
TOTAL |
|
$ |
287,755 |
|
|
$ |
263,321 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
CURRENT LIABILITIES: |
|
|
|
|
|
|
|
|
Revolving line-of-credit facilities |
|
$ |
15,336 |
|
|
$ |
11,218 |
|
Accounts payable |
|
|
11,364 |
|
|
|
9,444 |
|
Accrued expenses and other liabilities |
|
|
16,046 |
|
|
|
13,160 |
|
Deferred income taxes |
|
|
1,305 |
|
|
|
564 |
|
Income taxes payable |
|
|
1,353 |
|
|
|
96 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
45,404 |
|
|
|
34,482 |
|
|
|
|
|
|
|
|
DEFERRED INCOME TAXES |
|
|
2,149 |
|
|
|
4,204 |
|
|
|
|
|
|
|
|
LONG-TERM DEBT |
|
|
20,000 |
|
|
|
20,000 |
|
|
|
|
|
|
|
|
COMMITMENTS AND CONTINGENCIES |
|
|
|
|
|
|
|
|
MINORITY INTERESTS |
|
|
4,801 |
|
|
|
4,455 |
|
|
|
|
|
|
|
|
STOCKHOLDERS EQUITY: |
|
|
|
|
|
|
|
|
Common stock, $0.0001 par value,
175,000,000 shares authorized;
44,206,335 shares issued and outstanding
at March 31, 2008; 44,012,341 shares
issued and outstanding at December 31,
2007 |
|
|
4 |
|
|
|
4 |
|
Additional paid-in capital |
|
|
276,203 |
|
|
|
275,506 |
|
Accumulated deficit |
|
|
(82,348 |
) |
|
|
(90,497 |
) |
Accumulated other comprehensive income |
|
|
21,542 |
|
|
|
15,167 |
|
|
|
|
|
|
|
|
Total stockholders equity |
|
|
215,401 |
|
|
|
200,180 |
|
|
|
|
|
|
|
|
TOTAL |
|
$ |
287,755 |
|
|
$ |
263,321 |
|
|
|
|
|
|
|
|
See notes to consolidated financial statements.
3
IPG PHOTONICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
|
|
2008 |
|
|
2007 |
|
|
|
(In thousands, except per share data) |
|
NET SALES |
|
$ |
52,876 |
|
|
$ |
41,753 |
|
COST OF SALES |
|
|
28,476 |
|
|
|
22,422 |
|
|
|
|
|
|
|
|
GROSS PROFIT |
|
|
24,400 |
|
|
|
19,331 |
|
|
|
|
|
|
|
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
Sales and marketing |
|
|
3,147 |
|
|
|
1,909 |
|
Research and development |
|
|
2,874 |
|
|
|
2,129 |
|
General and administrative |
|
|
5,839 |
|
|
|
4,241 |
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
11,860 |
|
|
|
8,279 |
|
|
|
|
|
|
|
|
OPERATING INCOME |
|
|
12,540 |
|
|
|
11,052 |
|
|
|
|
|
|
|
|
OTHER (EXPENSE) INCOME, NET: |
|
|
|
|
|
|
|
|
Interest (expense) income, net |
|
|
(95 |
) |
|
|
396 |
|
Other income, net |
|
|
47 |
|
|
|
44 |
|
|
|
|
|
|
|
|
Total other (expense) income |
|
|
(48 |
) |
|
|
440 |
|
|
|
|
|
|
|
|
INCOME BEFORE PROVISION FOR INCOME
TAXES AND MINORITY INTERESTS IN
CONSOLIDATED SUBSIDIARIES |
|
|
12,492 |
|
|
|
11,492 |
|
PROVISION FOR INCOME TAXES |
|
|
(3,997 |
) |
|
|
(4,507 |
) |
MINORITY INTERESTS IN CONSOLIDATED
SUBSIDIARIES |
|
|
(346 |
) |
|
|
(372 |
) |
|
|
|
|
|
|
|
NET INCOME |
|
$ |
8,149 |
|
|
$ |
6,613 |
|
|
|
|
|
|
|
|
NET INCOME PER SHARE: |
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.18 |
|
|
$ |
0.15 |
|
Diluted |
|
$ |
0.18 |
|
|
$ |
0.15 |
|
WEIGHTED-AVERAGE SHARES OUTSTANDING: |
|
|
|
|
|
|
|
|
Basic |
|
|
44,095 |
|
|
|
42,909 |
|
Diluted |
|
|
46,041 |
|
|
|
45,602 |
|
See notes to consolidated financial statements.
4
IPG PHOTONICS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
|
|
2008 |
|
|
2007 |
|
|
|
(In thousands) |
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
8,149 |
|
|
$ |
6,613 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
3,609 |
|
|
|
2,725 |
|
Deferred income taxes |
|
|
(2,032 |
) |
|
|
691 |
|
Stock-based compensation |
|
|
387 |
|
|
|
219 |
|
Other |
|
|
(223 |
) |
|
|
(454 |
) |
Provisions for inventory, warranty and bad debt |
|
|
1,710 |
|
|
|
763 |
|
Minority interests in consolidated subsidiaries |
|
|
346 |
|
|
|
372 |
|
Changes in assets and liabilities that (used) provided cash: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(2,188 |
) |
|
|
(2,351 |
) |
Inventories |
|
|
(7,298 |
) |
|
|
(3,284 |
) |
Prepaid expenses and other current assets |
|
|
618 |
|
|
|
(3,218 |
) |
Accounts payable |
|
|
798 |
|
|
|
(93 |
) |
Accrued expenses and other liabilities |
|
|
(649 |
) |
|
|
(550 |
) |
Income and other taxes payable |
|
|
2,132 |
|
|
|
(855 |
) |
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
5,359 |
|
|
|
578 |
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
|
Purchases of property, plant, equipment and intangible assets |
|
|
(12,962 |
) |
|
|
(7,262 |
) |
Proceeds from sale of property, plant and equipment |
|
|
20 |
|
|
|
57 |
|
Proceeds from sale of marketable securities |
|
|
4,450 |
|
|
|
|
|
Employee and stockholder loans repaid |
|
|
39 |
|
|
|
11 |
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(8,453 |
) |
|
|
(7,194 |
) |
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
Proceeds from line-of-credit facilities |
|
|
5,926 |
|
|
|
6,052 |
|
Payments on line-of-credit facilities |
|
|
(2,585 |
) |
|
|
(7,769 |
) |
Principal payments on long-term borrowings |
|
|
|
|
|
|
(18,177 |
) |
Exercise of employee stock options and related tax benefit from exercise |
|
|
310 |
|
|
|
23 |
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities |
|
|
3,651 |
|
|
|
(19,871 |
) |
|
|
|
|
|
|
|
EFFECT OF CHANGES IN EXCHANGE RATES ON CASH AND CASH EQUIVALENTS |
|
|
169 |
|
|
|
(51 |
) |
|
|
|
|
|
|
|
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
|
|
726 |
|
|
|
(26,538 |
) |
CASH AND CASH EQUIVALENTS Beginning of period |
|
|
37,972 |
|
|
|
75,667 |
|
|
|
|
|
|
|
|
CASH AND CASH EQUIVALENTS End of period |
|
$ |
38,698 |
|
|
$ |
49,129 |
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
|
|
|
|
|
|
|
|
Cash paid for interest |
|
$ |
108 |
|
|
$ |
242 |
|
|
|
|
|
|
|
|
Income taxes paid |
|
$ |
2,915 |
|
|
$ |
3,889 |
|
|
|
|
|
|
|
|
Non-cash transactions: |
|
|
|
|
|
|
|
|
Additions to property, plant and equipment included in accounts payable |
|
$ |
584 |
|
|
$ |
1,039 |
|
See notes to consolidated financial statements.
5
IPG PHOTONICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. BASIS OF PRESENTATION
The accompanying unaudited interim consolidated financial statements have been
prepared by IPG Photonics Corporation, or IPG, we, our, or the Company. Certain
information and footnote disclosures normally included in financial statements prepared
in accordance with generally accepted accounting principles in the United States of
America have been condensed or omitted pursuant to the rules and regulations of the
Securities and Exchange Commission. The consolidated financial statements include our
accounts and those of our subsidiaries. All intercompany balances have been eliminated
in consolidation. These consolidated financial statements should be read in conjunction
with the consolidated financial statements and notes thereto in our annual report on
Form 10-K for the year ended December 31, 2007.
In the opinion of our management, the unaudited financial information for the
interim periods presented reflects all adjustments necessary for a fair presentation of
our financial position, results of operations and cash flows. The results reported in
these consolidated financial statements are not necessarily indicative of results that
may be expected for the entire year.
2. RECENT ACCOUNTING PRONOUNCEMENTS
In September 2006, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements
(SFAS No. 157). SFAS No. 157 provides a single definition of fair value, along with a
framework for measuring it, and requires additional disclosure about using fair value
to measure assets and liabilities. SFAS No. 157 emphasizes that fair value measurement
is market-based, not entity-specific, and establishes a fair value hierarchy in which
the highest priority is quoted prices in active markets. Under SFAS No. 157, fair value
measurements are disclosed according to their level within this hierarchy. While SFAS
No. 157 does not add any new fair value measurements, it does change current practice
in certain ways, including requiring entities to include their own credit standing when
measuring their liabilities. SFAS No. 157 was initially effective for the Companys
fiscal year beginning January 1, 2008. However, in February 2008, the FASB decided that
an entity need not apply this standard to nonfinancial assets and liabilities disclosed
at fair value in the financial statements on a nonrecurring basis until the subsequent
year. Accordingly, the Companys adoption of this standard on January 1, 2008 is
limited to financial assets and liabilities and adoption did not have a material effect
on our results of operations or financial condition. However, the Company is still in
the process of evaluating this standard with respect to its effect on nonfinancial
assets and liabilities and therefore has not yet determined the impact that it will
have on its financial statements upon full adoption.
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for
Financial Assets and Financial Liabilities (SFAS No. 159), which provides companies
with an option to report selected financial assets and liabilities at fair value. SFAS
No. 159 also establishes presentation and disclosure requirements relating to the use
of fair values within the financial statements. The provisions of SFAS No. 159 were
effective for the Company beginning January 1, 2008. The Company did not designate any
financial assets or liabilities for the accounting allowed by SFAS No. 159, and
therefore there was no material impact on adoption.
In December 2007, the FASB issued SFAS No. 141 (revised 2007), Business
Combinations (SFAS No. 141 (revised 2007)), and SFAS No. 160, Noncontrolling
Interests in Consolidated Financial Statements-an amendment of ARB No. 51 (SFAS No.
160). SFAS No. 141 (revised 2007) requires an acquirer to measure the identifiable
assets acquired, the liabilities assumed and any noncontrolling interest in the
acquiree at their fair values on the acquisition date, with goodwill being the excess
value over the net identifiable assets acquired. This standard also requires the fair
value measurement of certain other assets and liabilities related to the acquisition
such as contingencies and research and development. SFAS No. 160 clarifies that a
noncontrolling interest in a subsidiary should be reported as a component of
stockholders equity in the consolidated financial statements. Consolidated net income
should include the net income for both the parent and the noncontrolling interest with
disclosure of both amounts on the consolidated statement of income. The calculation of
earnings per share will continue to be based on income amounts attributable to the
parent. The effective date for both statements is for fiscal years beginning after
December 15, 2008. The adoption of SFAS No. 141 (revised 2007) is prospective. The
adoption of SFAS No. 160 is prospective. The impact on presentation and disclosure is
applied
retrospectively. We are currently in the process of evaluating the impact, if any,
that the adoption of SFAS No. 141 (revised 2007) and SFAS No. 160 will have on our
financial position, consolidated results of operations and cash flows.
6
3. INVENTORIES
Inventories consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2008 |
|
|
2007 |
|
Components and raw materials |
|
$ |
25,876 |
|
|
$ |
25,363 |
|
Work-in-process |
|
|
31,456 |
|
|
|
25,831 |
|
Finished goods |
|
|
12,298 |
|
|
|
9,218 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
69,630 |
|
|
$ |
60,412 |
|
|
|
|
|
|
|
|
4. FINANCING ARRANGEMENTS
The Companys borrowings under existing financing arrangements consist of the following
(in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2008 |
|
|
2007 |
|
Revolving Line-of-Credit Facilities: |
|
|
|
|
|
|
|
|
Euro Overdraft Facilities |
|
$ |
114 |
|
|
$ |
135 |
|
U.S. Line of Credit |
|
|
14,205 |
|
|
|
11,083 |
|
Japanese Line of Credit |
|
|
1,017 |
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
15,336 |
|
|
$ |
11,218 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term Debt: |
|
|
|
|
|
|
|
|
Subordinated Notes |
|
|
20,000 |
|
|
|
20,000 |
|
|
|
|
|
|
|
|
Total long-term debt |
|
$ |
20,000 |
|
|
$ |
20,000 |
|
|
|
|
|
|
|
|
5. NET INCOME PER SHARE
The following table sets forth the computation of diluted net income per share (in
thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
|
|
Ended March 31, |
|
|
|
2008 |
|
|
2007 |
|
Net income |
|
$ |
8,149 |
|
|
$ |
6,613 |
|
|
Weighted average shares |
|
|
44,095 |
|
|
|
42,909 |
|
Dilutive effect of common stock
equivalents |
|
|
1,946 |
|
|
|
2,693 |
|
|
|
|
|
|
|
|
Diluted weighted average common shares |
|
|
46,041 |
|
|
|
45,602 |
|
|
|
|
|
|
|
|
Basic net income per share |
|
$ |
0.18 |
|
|
$ |
0.15 |
|
|
|
|
|
|
|
|
Diluted net income per share |
|
$ |
0.18 |
|
|
$ |
0.15 |
|
|
|
|
|
|
|
|
The computation of diluted weighted average common shares excludes 66,000 and
5,000 shares for the three months ended March 31, 2008 and 2007, respectively,
because the effect on net income per share would have been anti-dilutive.
7
6. COMPREHENSIVE INCOME
Total comprehensive income and its components were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
|
|
2008 |
|
|
2007 |
|
Net income |
|
$ |
8,149 |
|
|
$ |
6,613 |
|
Other comprehensive income: |
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
|
6,375 |
|
|
|
575 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income |
|
$ |
14,524 |
|
|
$ |
7,188 |
|
|
|
|
|
|
|
|
Total accumulated other comprehensive income at each balance sheet date is comprised
solely of the cumulative translation adjustment related to our foreign operations.
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
You should read the following discussion in conjunction with our consolidated
financial statements and related notes included elsewhere in this Quarterly Report on
Form 10-Q. This discussion contains forward looking statements that are based on
managements current expectations, estimates and projections about our business and
operations. Our actual results may differ materially from those currently anticipated
and expressed in such forward-looking statements. See Cautionary Statement Regarding
Forward-Looking Statements.
Overview
We develop and manufacture a broad line of high-performance fiber lasers, fiber
amplifiers and diode lasers for diverse applications in numerous markets. Our diverse
lines of low, mid and high-power lasers and amplifiers are used in materials processing,
advanced, communications and medical applications. We sell our products globally to
original equipment manufacturers, or OEMs, system integrators and end users. We market
our products internationally primarily through our direct sales force and also through
agreements with independent sales representatives and distributors.
We are vertically integrated such that we design and manufacture all key components
used in our finished products, from semiconductor diodes to optical fiber preforms,
finished fiber lasers and amplifiers. Since our formation in 1990, we have been focused
on developing and manufacturing high-power fiber lasers and amplifiers.
Factors and Trends That Affect Our Operations and Financial Results
In reading our financial statements, you should be aware of the following factors
and trends that our management believes are important in understanding our financial
performance.
Net sales. Our net sales have historically fluctuated from quarter to quarter. The
increase or decrease in sales from a prior quarter can be affected by the timing of
orders received from customers, the shipment, installation and acceptance of products at
our customers facilities, the mix of OEM orders and one-time orders for products with
large purchase prices, and seasonal factors such as the purchasing patterns and levels
of activity throughout the year in the regions where we operate. Historically, our net
sales have been higher in the second half of the year than in the first half of the
year. Furthermore, net sales can be affected by the time taken to qualify our products
for use in new applications in the end markets that we serve. The adoption of our
products by a new customer or qualification in a new application can lead to an increase
in net sales for a period, which may then slow until we further penetrate new markets or
obtain new customers.
Gross margin. Our total gross margin in any period can be affected by total net
sales in any period, product mix, that is, the percentage of our revenue in that period
that is attributable to higher or lower-power products, production volumes, and by other
factors, some of which are not under our control. Our product mix affects our margins
because the selling price per watt is higher for low and mid-power devices than for
high-power devices. The overall cost of high-power lasers may be partially offset by
improved absorption of fixed overhead costs associated with sales of larger volumes of
higher-power products.
8
Due to the fact that we have high fixed costs, our costs are difficult to adjust in
response to changes in demand. In addition, our fixed costs will increase as we expand
our capacity. Gross margins generally have improved because of greater absorption of
fixed overhead costs associated with an increase in sales. In addition, absorption of
fixed costs can benefit gross margins due to an increase in production that is not sold
and placed into inventory. Absorption of fixed costs can adversely impact gross margins
by lower production and a decrease in inventory that is sold. If the rate at which our
fixed costs increases is greater than the growth rate of our net sales or if we have
production issues or inventory write-downs, our gross margins could be negatively
affected. We also regularly review our inventory for items that are slow-moving, have
been rendered obsolete or determined to be excess, and any write-off of such
slow-moving, obsolete or excess inventory affects our gross margins.
Sales and marketing expense. We expect to continue to expand our worldwide direct
sales organization, build and expand applications centers, hire additional personnel
involved in marketing in our existing and new geographic locations, increase the number
of units used for demonstration purposes and otherwise increase expenditures on sales
and marketing activities in order to support the growth in our net sales. As such, we
expect that our sales and marketing expenses will increase in the aggregate.
Research and development expense. We plan to continue to invest in research and
development to improve our existing components and products and develop new components
and products. We plan to increase the personnel involved in research and development and
expect to increase other research and development expenses. As such, we expect that our
research and development expenses will increase in the aggregate.
General and administrative expense. We expect our general and administrative
expenses to continue to increase as we expand headcount to support the growth of our
company, comply with public company reporting obligations and regulatory requirements,
incur higher insurance expenses related to directors and officers insurance and
continue to invest in our financial reporting systems. We expect future increases in
these expenses to be more moderate than those that we experienced in 2007. Legal
expenses are expected to increase in response to pending litigation and may increase in
response to any future litigation or intellectual property matters, the timing and
amount of which may vary substantially from quarter to quarter.
Major customers. We have historically depended on a few customers for a large
percentage of our annual net sales. The composition of this group can change from year
to year. Net sales derived from our five largest customers as a percentage of our annual
net sales were 37% in 2005, 29% in 2006, 20% in 2007, and 22% for the three months ended
March 31, 2008. Sales to our largest customer accounted for 13%, 10%, 7% and 8% of our
net sales in 2005, 2006, 2007 and the three months ended March 31, 2008, respectively.
We seek to add new customers and to expand our relationships with existing customers. We
anticipate that the composition of our net sales to our significant customers will
continue to change. If any of our significant customers were to substantially reduce
their purchases from us, our results would be adversely affected.
Results of Operations for the three months ended March 31, 2008 compared to the three
months ended March 31, 2007
Net sales. Net sales increased by $11.1 million, or 26.6%, to $52.9 million for the
three months ended March 31, 2008 from $41.8 million for the three months ended March
31, 2007. This increase was attributable to higher sales of fiber lasers in materials
processing applications, where net sales increased by $11.3 million, or 34.4%, advanced
applications, where net sales increased by $0.7 million, or 15.9%, and communications
applications, where net sales increased by $0.7 million, or 28.6%. These increases were
partially offset by a decrease in sales in medical applications of $1.6 million, or
77.2%. The growth in materials processing applications and advanced applications sales
resulted primarily from increased sales of pulsed lasers and medium-power lasers and
continued market penetration for high-power fiber lasers. The increase in communications
applications sales was due to higher sales of fiber amplifiers in Russia. The decrease
in sales of medical applications was due to lower sales to our largest customer for this
application in the United States and resulted in a decrease in sales of low-power
lasers.
Cost of sales and gross margin. Cost of sales increased by $6.1 million, or 27.0%,
to $28.5 million for the three months ended March 31, 2008 from $22.4 million for the
three months ended March 31, 2007 as a result of increased sales volume. Our gross
margin decreased slightly to 46.1% for the three months ended March 31, 2008 from 46.3%
for the three months ended March 31, 2007. The decrease in gross margin was the result
of less favorable absorption of our fixed manufacturing costs offset by a favorable
product mix in the quarter ended March 31, 2008. Manufacturing expenses increased as we
continued to expand our vertically integrated manufacturing capacity and resulted in
higher expenses related to
9
manufacturing salaries and benefits, facilities, supplies and
tooling and depreciation. Part of our capacity in the first quarter of both 2007 and
2008 was used to produce product that was placed in inventory.
Sales and marketing expense. Sales and marketing expense increased by $1.2 million,
or 64.9%, to $3.1 million for the three months ended March 31, 2008 from $1.9 million
for the three months ended March 31, 2007, primarily as a result of an increase of $0.4
million in selling expenses related to an increase in the number of units used for
demonstration purposes and an increase of $0.4 million in personnel costs related to the
expansion of our worldwide direct sales organization, including our new sales and
service center in China and additional sales personnel in the United States, Germany and
Japan. The remainder of the increase related to increases in costs for trade fairs,
travel, premises and depreciation. As a percentage of sales, sales and marketing
expense increased to 6.0% for the three months ended March 31, 2008 from 4.6% for the
three months ended March 31, 2007. As we continue to expand our worldwide sales
organization, we expect expenditures on sales and marketing to continue to increase in
the aggregate.
Research and development expense. Research and development expense increased by
$0.8 million, or 35.0%, to $2.9 million for the three months ended March 31, 2008 from
$2.1 million for the three months ended March 31, 2007. This increase was primarily due
to an increase of $0.6 million in personnel costs. Research and development activity
continues to focus on enhancing the performance of our internally manufactured
components, refining production processes to improve manufacturing yields and the
development of new products operating at different wavelengths and at higher output
powers. As a percentage of sales, research and development expense increased to 5.4%
for the three months ended March 31, 2008 from 5.1% for the three months ended March 31,
2007.
General and administrative expense. General and administrative expense increased by
$1.6 million, or 37.7%, to $5.8 million for the three months ended March 31, 2008 from
$4.2 million for the three months ended March 31, 2007, primarily due to an increase of
$0.9 million in legal costs due to patent litigation defense fees and a $0.7 million
increase in personnel expenses as we expanded the general and administrative function to
support the growth of the business, and increased expenses related to the office in
China we opened in the second quarter of 2007. Expenses for patent litigation were
higher in the quarter due to increased activity in one patent litigation and a new
patent litigation brought against the Company in the three months ended March 31, 2008.
As a percentage of sales, general and administrative expense increased to 11.0% for the
three months ended March 31, 2008 from 10.2% for the three months ended March 31, 2007.
Interest income (expense), net. Interest income (expense), net was $0.1 million of
net interest expense for the three months ended March 31, 2008 compared to $0.4 million
of net interest income for the three months ended March 31, 2007. The change in interest
income (expense), net resulted from higher interest expense due to utilization of credit
lines.
(Provision for) benefit from income taxes. Provision for income taxes decreased by
$0.5 million to $4.0 million for the three months ended March 31, 2008 from $4.5 million
for the three months ended March 31, 2007, representing an effective tax rate of 32.0%
for the three months ended March 31, 2008 as compared to an effective tax rate of 39.2%
for the three months ended March 31, 2007. The decrease is primarily due to a change in
income tax rates in Germany from 38% to approximately 30% which became effective on
January 1, 2008.
Net income. Net income increased by $1.5 million to $8.1 million for the three
months ended March 31, 2008 from $6.6 million for the three months ended March 31, 2007.
Net income as a percentage of our net sales decreased by 0.4 percentage points to 15.4%
for the three months ended March 31, 2008 from 15.8% for the three months ended March
31, 2007 due to the factors described.
Liquidity and Capital Resources
Our principal sources of liquidity as of March 31, 2008 consisted of cash and cash
equivalents of $38.7 million, marketable securities of $1.0 million, unused credit lines
and overdraft facilities of $39.1 million and working capital
(excluding cash) of $81.3 million. This compares to cash and cash equivalents of
$38.0 million, marketable securities of $7.0 million, unused overdraft facilities of
$39.9 million and working capital (excluding cash) of $83.2 million as of December 31,
2007. The increase in cash and cash equivalents of $0.7 million from December 31, 2007
relates primarily to cash provided by operating activities during the first quarter of
2008, sales of marketable securities of $4.5 million and net proceeds from our credit
lines of $3.3 million, partially offset by capital expenditures and the acquisition of
intangible assets totaling $13.0 million.
10
We held approximately $2.5 million in auction-rate securities (ARSs) at March 31,
2008, of which $1.0 million is included in marketable securities and $1.5 million in
other long-term assets, as compared to $7.0 million at December 31, 2007. Our
investments in ARSs at March 31, 2008 consisted solely of taxable municipal debt
securities. None of the ARSs in our portfolio are collateralized debt obligations
(CDOs) or mortgage-backed securities.
The most recent auctions for these ARSs in April 2008 failed and it is uncertain
whether future auctions relating to these securities will be successful in resetting a
market rate of interest for the ARSs. If an auction is unsuccessful, the terms of the
ARSs provide that the issuer will pay interest at the maximum contractual rate and that
we will hold these securities until their next scheduled auction reset dates. In May
2008, we received a notice of full call for redemption for $1.0 million of the ARSs we
held. The scheduled redemption date is May 15th, 2008. For the $1.5 million
of the ARSs not scheduled for redemption, the auction reset dates for the ARSs occur
every 35 days. Our ability to dispose of these ARSs at the subsequent auction reset
date depends on whether or not the auction is successful. Therefore, failed auctions
may limit the short-term liquidity of these investments.
As a result of the recent auction failures, we continue to hold the ARSs not
subject to redemption and the issuers are required to pay interest on the ARSs at the
maximum contractual rate. While these auction failures have affected our ability to
access these funds in the near term, we do not believe that the fair value of the ARSs
has been affected because no default has occurred, the ARSs are insured, and they are
rated Aaa/AAA by Moodys and Standard & Poors and AA by Fitch. We have classified
these ARSs as other long-term assets. If the credit rating of the issuer of the ARSs
were to deteriorate, we may be required to adjust the carrying value of these
investments by recording an impairment charge. Based on our ability to access our cash,
our expected operating cash flows and our available credit lines, we do not expect that
the current lack of liquidity in our investments in ARSs will have a material impact on
our overall liquidity, financial condition, or results of operations.
Our long-term debt consists of $20.0 million subordinated, unsecured, variable-rate
notes described in Note 4 to our consolidated financial statements, which mature in
December 2010. We expect that the existing cash and marketable securities, our cash
flows from operations and our existing lines of credit will be sufficient to meet our
liquidity and capital needs for the foreseeable future. Our future long-term capital
requirements will depend on many factors including our rate of net sales growth, the
timing and extent of spending to support development efforts, the expansion of our sales
and marketing activities, the timing and introductions of new products, the need to
ensure access to adequate manufacturing capacity and the continuing market acceptance of
our products. We have made no arrangements to obtain additional financing, and there is
no assurance that such additional financing, if required or desired, will be available
in amounts or on terms acceptable to us, if at all.
Although we repaid substantially all our fixed-term debt in the first quarter of
2007, we intend to maintain and use availability under our lines of credit to finance
our short-term working capital requirements that may arise from time to time.
11
The following table details our line-of-credit facilities as of March 31, 2008:
|
|
|
|
|
|
|
|
|
Description |
|
Available Principal |
|
Interest Rate |
|
Maturity |
|
Security |
|
|
|
|
|
|
|
|
|
U.S. Revolving Line |
|
Up to $20 million |
|
LIBOR plus 0.8% to |
|
July 2010 |
|
Unsecured |
of Credit (1) |
|
|
|
1.2%, depending on |
|
|
|
|
|
|
|
|
the Companys |
|
|
|
|
|
|
|
|
performance |
|
|
|
|
|
|
|
|
|
|
|
|
|
Euro Credit |
|
Euro 15.0 million |
|
5.60% |
|
June 2010 |
|
Unsecured, |
Facility (Germany) |
|
($23.7 million) |
|
|
|
|
|
guaranteed by |
(2) |
|
|
|
|
|
|
|
parent company |
|
|
|
|
|
|
|
|
|
Euro Overdraft |
|
Euro 3.0 million |
|
6.20%-6.95% |
|
Between September |
|
Common pool of |
Facilities |
|
($4.7 million) |
|
|
|
2008 and September |
|
assets of German |
|
|
|
|
|
|
2009 |
|
and Italian |
|
|
|
|
|
|
|
|
subsidiaries |
|
|
|
|
|
|
|
|
|
Japanese Overdraft |
|
JPY 600 million |
|
2.5% |
|
September 2008 |
|
Common pool of |
Facility |
|
($6.0 million) |
|
|
|
|
|
assets of Japanese |
|
|
|
|
|
|
|
|
subsidiary |
|
|
|
(1) |
|
The available principal under this facility can be increased to $25
million pursuant to certain notice requirements and other conditions. |
|
(2) |
|
This credit facility bears interest at Euribor + 1.0% or EONIA + 1.0%. |
The financial covenants in our loan documents may cause us to not take or to delay
investments and actions that we might otherwise undertake because of limits on capital
expenditures and amounts that we can borrow or lease. In the event that we do not comply
with any one of these covenants, we would be in default under the loan agreement or loan
agreements, which may result in acceleration of the debt, cross-defaults on other debt
or a reduction in available liquidity, any of which could harm our results of operations
and financial condition. We were in compliance with all financial covenants of our loan
agreements as of March 31, 2008.
Operating activities. Net cash provided by operating activities in the three months
ended March 31, 2008 increased by $4.7 million to $5.3 million from $0.6 million in the
three months ended March 31, 2007. The increase in cash provided by operating activities
in the first quarter of 2008 compared to the first quarter of 2007 primarily resulted
from:
|
|
|
an increase in net income after adding back non-cash charges of
$1.0 million; |
|
|
|
|
an increase in accounts payable of $0.8 million in 2008 as compared
to a decrease of $0.1 million in 2007; |
|
|
|
|
an increase in taxes payable of $2.1 million in 2008 as compared to
a decrease of $0.9 million due to tax prepayments in Germany in 2007; |
|
|
|
|
a decrease in prepayments and other current assets of $0.6 million
in 2008 compared to an increase of $3.2 million in 2007; partially
offset by |
|
|
|
|
cash used to finance inventory of $7.3 million in 2008 compared to
cash used of $3.3 million in 2007 primarily related to an increase in
work in process and finished goods. |
Given our vertical integration, rigorous and time-consuming testing procedures for
both internally manufactured and externally purchased components and the lead time
required to manufacture components used in our finished product, the rate at which we
turn inventory has historically been low when compared to our cost of sales. We do not
expect this to change significantly in the future and believe that we will have to
maintain a relatively high level of inventory compared to our cost of sales. As a
result, we continue to expect to have a significant amount of working capital invested
in inventory and for changes in our level of inventory to lead to an increase in cash
generated from our operations when it is sold or a decrease in cash generated from our
operations at times when the amount of inventory is increasing. A reduction in our level
of net sales or the rate of growth of our net sales from their current levels would mean
that the rate at which we are able to convert our inventory into accounts receivable
would decrease.
Investing activities. Net cash used in investing activities was $8.5 million and
$7.2 million in the three months ended March 31, 2008 and 2007, respectively. The cash
used in investing activities in 2008 was primarily related to $13.0 million of capital
expenditures on property, plant and equipment and intangible assets which was partially
offset by $4.5 million of proceeds from the sale of marketable securities. The cash
used in investing activities in 2007 was related to capital expenditures on property,
plant and equipment of $7.3 million, primarily in the United States and Germany. In 2008
and 2007, capital expenditures in the United States, Germany, and Russia related to
facilities and equipment for diode wafer growth, burn-in test stations and packaging as
well as new fiber assembly and component production facilities. We expect capital
expenditures, excluding intangible assets, in the range of $32 million to $35 million
for the year ended December 31, 2008. We expect to continue to invest in property, plant
and equipment and to use a significant amount of our cash generated from operations to
finance capital expenditures, including the expansion of our manufacturing capacity, the
acquisition of additional sales and application facilities and the purchase of
production equipment. The timing and extent of any capital expenditures in and between
periods can have a significant effect on our cash flow. Many of the capital expenditure
projects that we undertake have long lead times and are difficult to cancel or defer in
the event that our net sales are reduced or if our rate of growth slows, with the result
that it would be difficult to defer committed capital expenditures to a later period.
12
Financing activities. Net cash provided by financing activities was $3.7 million in
2008 as compared to net cash used by financing activities of $19.9 million in 2007. The
cash provided by financing activities in 2008 was related to the net
proceeds of $3.3 million from the use of our credit lines. Net cash used by
financing activities in 2007 related to repayment of our long-term bank debt and credit
lines.
Cautionary Statement Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and we intend that such forward-looking statements be
subject to the safe harbors created thereby. For this purpose, any statements contained
in this Quarterly Report on Form 10-Q except for historical information are
forward-looking statements. Without limiting the generality of the foregoing, words such
as may, will, expect, believe, anticipate, intend, could, estimate, or
continue or the negative or other variations thereof or comparable terminology are
intended to identify forward-looking statements. In addition, any statements that refer
to projections of our future financial performance, trends in our businesses, or other
characterizations of future events or circumstances are forward-looking statements.
The forward-looking statements included herein are based on current expectations of
our management based on available information and involve a number of risks and
uncertainties, all of which are difficult or impossible to accurately predict and many
of which are beyond our control. As such, our actual results may differ significantly
from those expressed in any forward-looking statements. Factors that may cause or
contribute to such differences include, but are not limited to, those discussed in more
detail in Item 1, Business and Item 1A, Risk Factors of Part I of our Annual Report
on Form 10-K for the period ended December 31, 2007. Readers should carefully review
these risks, as well as the additional risks described in other documents we file from
time to time with the Securities and Exchange Commission. In light of the significant
risks and uncertainties inherent in the forward-looking information included herein, the
inclusion of such information should not be regarded as a representation by us or any
other person that such results will be achieved, and readers are cautioned not to rely
on such forward-looking information. We undertake no obligation to revise the
forward-looking statements contained herein to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events.
Recent Accounting Pronouncements
The Company adopted SFAS No. 157, Fair Value Measurements (SFAS No. 157)
effective January 1, 2008. The provisions of SFAS No. 157 are more fully described in
the Notes to Consolidated Financial Statements in Part I, Item 1. The Companys initial
adoption of SFAS No. 157 did not have a material effect on its financial condition or
results of operations. However, the Company is still in the process of evaluating this
standard with respect to its effect on nonfinancial assets and liabilities and therefore
has not yet determined the impact that it will have on its financial statements upon
full adoption.
The Company also adopted SFAS No. 159, The Fair Value Option for Financial Assets
and Financial Liabilities (SFAS No. 159) effective January 1, 2008., The provisions of
SFAS No. 157 are more fully described in the Notes to Consolidate Financial Statements
in Part I, Item 1. The Company did not designate any financial assets or liabilities for
the accounting allowed by SFAS No. 159, and therefore there was no material impact on
adoption.
In December 2007, the FASB issued SFAS No. 141 (revised 2007), Business
Combinations (SFAS No. 141 (revised 2007)), and SFAS No. 160, Noncontrolling Interests
in Consolidated Financial Statements-an amendment of ARB No. 51 (SFAS No. 160). The
provisions of these pronouncements are more fully described in the Consolidated Notes to
Financial Statements in Part I, Item 1. The effective date for both statements is for
fiscal years beginning after December 15, 2008. The Company is currently in the process
of evaluating the impact, if any, that the adoption of SFAS No. 141 (revised 2007) and
SFAS No. 160 will have on our financial position, consolidated results of operations and
cash flows.
13
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to market risk in the ordinary course of business, which consists
primarily of interest rate risk associated with our cash and cash equivalents and our
debt and foreign exchange rate risk.
Auction Rate Securities. We held approximately $2.5 million in auction-rate
securities (ARSs) at March 31, 2008, of which $1.0 million is included in marketable
securities and $1.5 million in other long-term assets, as compared to $7.0
million at December 31, 2007. Our investments in ARSs at March 31, 2008 consisted
solely of taxable municipal debt securities. None of the ARSs in our portfolio are
collateralized debt obligations (CDOs) or mortgage-backed securities.
The most recent auctions for these ARSs in April 2008 failed and it is uncertain
whether future auctions relating to these securities will be successful in resetting a
market rate of interest for the ARSs. If an auction is unsuccessful, the terms of the
ARSs provide that the issuer will pay interest at the maximum contractual rate and that
we will hold these securities until their next scheduled auction reset dates. In May
2008, we received a notice of a call for full redemption for $1.0 million of the ARSs we
held. The scheduled redemption date is May 15th, 2008. For the $1.5 million
of the ARSs not scheduled for redemption, the auction reset dates for the ARSs occur
every 35 days. Our ability to dispose of these ARSs at the subsequent auction reset
date depends on whether or not the auction is successful. Therefore, failed auctions
may limit the short-term liquidity of these investments.
While these auction failures have affected our ability to access these funds in the
near term, we do not believe that the fair value of the ARSs has been affected because
no default has occurred, the ARSs are insured, and they are rated Aaa/AAA by Moodys and
Standard & Poors and AA by Fitch. If the credit rating of the issuer of the ARSs were
to deteriorate, we may be required to adjust the carrying value of these investments by
recording an impairment charge.
Interest rate risk. Our investments have limited exposure to interest risk. To
minimize this risk, we maintain a portfolio of cash, cash equivalents and short-term
investments, consisting primarily of bank deposits, money market funds and short-term
government funds. The interest rates are variable and fluctuate with current market
conditions. Because of the short-term nature of these instruments, a sudden change in
market interest rates would not be expected to have a material impact on our financial
condition or results of operations.
Our exposure to interest risk also relates to the increase or decrease in the
amount of interest expense we must pay on our bank debt and borrowings on our bank
credit facilities. The interest rate on our existing bank debt is currently fixed except
for our U.S. revolving line of credit. The rates on our Euro overdraft facilities in
Germany and Italy and our Japanese Yen overdraft facility are fixed for twelve-month
periods. Approximately 57% of our outstanding debt had a fixed rate of interest as of
March 31, 2008. All of our U.S. and German term debt was repaid in the first quarter of
2007 except for the $20 million of subordinated notes issued to our series B
stockholders upon completion of our IPO. We do not believe that a 10% change in market
interest rates would have a material impact on our financial position or results of
operations.
Exchange rates. Due to our international operations, a significant portion of our
net sales, cost of sales and operating expenses are denominated in currencies other than
the U.S. dollar, principally the Euro and the Japanese Yen. As a result, our
international operations give rise to transactional market risk associated with exchange
rate movements of the U.S. dollar, the Euro and the Japanese Yen. Gains on foreign
exchange transactions are reported as a component of general and administrative expense
and totaled $0.5 million and $0.5 million for the three months ended March 31, 2008 and
2007, respectively. Changes in exchange rates can also affect our financial results.
If exchange rates in the three months ended March 31, 2008 had been the same as in the
previous year, we estimate that our sales would have been lower by approximately $3.2
million. Additionally, we estimate that cost of sales and operating expenses would have
been lower by approximately $2.2 million for the three months ended March 31, 2008.
No derivative instruments were outstanding at March 31, 2008. Management believes
that the use of foreign currency financial instruments reduces the risks of certain
foreign currency transactions, however, these instruments provide only limited
protection. We will continue to analyze our exposure to currency exchange rate
fluctuations and may engage in additional financial hedging techniques in the future to
attempt to minimize the effect of these potential fluctuations. Exchange rate
fluctuations may adversely affect our financial results in the future.
14
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision of our chief executive officer and our chief financial
officer, our management has evaluated the effectiveness of the design and operation of
our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)
promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act)),
as of the end of the
period covered by this Quarterly Report on Form 10-Q (the Evaluation Date). Based upon
that evaluation, our chief executive officer and our chief financial officer have
concluded that, as of the Evaluation Date, our disclosure controls and procedures are
effective.
Changes in Internal Controls
There was no change in our internal control over financial reporting (as defined in
Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act) that occurred during
the last fiscal quarter that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.
PART IIOTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, we are party to various legal proceedings and other disputes
incidental to our business. There have been no material developments in the first
quarter of 2008 with respect to those proceedings previously reported in our Annual
Report on Form 10-K for the year ended December 31, 2007, except that the U.S. District
Court stayed the litigation in an action filed by IMRA America, Inc. until the
conclusion of the U.S. Patent and Trademark Office (the USPTO) re-examination of the
patent. We petitioned the USPTO to re-examine the patent based on several prior art
references, which request has not yet been granted.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully
consider the factors discussed in Part I, Item 1A. Risk Factors in our Annual Report
on Form 10-K for the year ended December 31, 2007, which could materially affect our
business, financial condition or future results. The risks described in our Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q are not the only risks facing our
Company. Additional risks and uncertainties not currently known to us or that we
currently deem to be immaterial also may materially adversely affect our business,
financial condition and/or operating results.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
ITEM 5. OTHER INFORMATION
None.
ITEM 6. EXHIBITS
(a) Exhibits
|
|
|
Exhibit |
|
|
No. |
|
Description |
|
|
|
31.1 |
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) |
|
|
|
31.2 |
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) |
|
|
|
32 |
|
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 1350 |
15
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this Report to be signed on its behalf by the undersigned thereunto duly
authorized.
|
|
|
|
|
|
IPG PHOTONICS CORPORATION
|
|
Date: May 9, 2008 |
By: |
/s/ Valentin P. Gapontsev
|
|
|
|
Valentin P. Gapontsev |
|
|
|
Chairman and Chief Executive Officer
(Principal Executive Officer) |
|
|
|
|
|
|
|
|
|
|
Date: May 9, 2008 |
By: |
/s/ Timothy P.V. Mammen
|
|
|
|
Timothy P.V. Mammen |
|
|
|
Vice President and Chief Financial Officer
(Principal Financial Officer) |
|
|
16